DK0975764T3 - Gentilförselsbærer, som eksprimerer de apoptosis-fremkaldende proteiner VP2 og/eller apoptin - Google Patents
Gentilförselsbærer, som eksprimerer de apoptosis-fremkaldende proteiner VP2 og/eller apoptinInfo
- Publication number
- DK0975764T3 DK0975764T3 DK98914146T DK98914146T DK0975764T3 DK 0975764 T3 DK0975764 T3 DK 0975764T3 DK 98914146 T DK98914146 T DK 98914146T DK 98914146 T DK98914146 T DK 98914146T DK 0975764 T3 DK0975764 T3 DK 0975764T3
- Authority
- DK
- Denmark
- Prior art keywords
- apoptosis
- apoptin
- relates
- expresses
- inducing proteins
- Prior art date
Links
- 101710094856 Apoptin Proteins 0.000 title abstract 2
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 title abstract 2
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title 1
- 238000001476 gene delivery Methods 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- 241000725585 Chicken anemia virus Species 0.000 abstract 1
- 206010058314 Dysplasia Diseases 0.000 abstract 1
- 206010054949 Metaplasia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108010067390 Viral Proteins Proteins 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 230000006882 induction of apoptosis Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 230000015689 metaplastic ossification Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97201121A EP0872552A1 (de) | 1997-04-15 | 1997-04-15 | Genabgabe-Vehikel die das Apoptosis VP2 induzierendes Protein und/oder Apoptin exprimiert |
| EP97203595A EP0878546A1 (de) | 1997-04-15 | 1997-11-18 | Genabgabe-Vehikel die das Apoptosis VP2 inducierendes Protein, und/oder Apoptin exprimiert |
| EP98914146A EP0975764B1 (de) | 1997-04-15 | 1998-04-15 | Genabgabe-vehikel die das apoptosis vp2 inducierendes protein, und/oder apoptin exprimiert |
| PCT/NL1998/000213 WO1998046760A1 (en) | 1997-04-15 | 1998-04-15 | A gene delivery vehicle expressing the apoptosis-inducing proteins vp2 and/or apoptin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0975764T3 true DK0975764T3 (da) | 2005-01-03 |
Family
ID=26146368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK98914146T DK0975764T3 (da) | 1997-04-15 | 1998-04-15 | Gentilförselsbærer, som eksprimerer de apoptosis-fremkaldende proteiner VP2 og/eller apoptin |
Country Status (17)
| Country | Link |
|---|---|
| EP (2) | EP0878546A1 (de) |
| JP (1) | JP2001521387A (de) |
| KR (1) | KR100528755B1 (de) |
| AT (1) | ATE275200T1 (de) |
| AU (1) | AU750162B2 (de) |
| BR (1) | BR9808542A (de) |
| CA (1) | CA2286165C (de) |
| CZ (1) | CZ299963B6 (de) |
| DE (1) | DE69825978T2 (de) |
| DK (1) | DK0975764T3 (de) |
| ES (1) | ES2227822T3 (de) |
| NO (1) | NO994967L (de) |
| NZ (1) | NZ500012A (de) |
| PL (1) | PL196607B1 (de) |
| PT (1) | PT975764E (de) |
| SK (1) | SK285724B6 (de) |
| WO (1) | WO1998046760A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL196605B1 (pl) | 1997-08-12 | 2008-01-31 | Leadd Bv | Sposób oznaczania zdolności transformującej, sposób oznaczania predyspozycji do przekształcania się w komórkę nowotworową, sposób oznaczania predyspozycji do dziedziczenia rodzajów raka, sposób oznaczania mutacji genu i diagnostyczny zestaw testowy |
| DE60003632T2 (de) * | 1999-01-11 | 2004-04-15 | Leadd B.V. | Verwendung von apoptose-induzierende mittel zur herstellung eines mittels zur behandlung von (auto)immunkrankheiten |
| AU2004233486B2 (en) * | 1999-01-11 | 2007-09-13 | Leadd B.V. | Use of apoptosis inducing agents in the treatment of (auto)immune diseases |
| CA2383784A1 (en) * | 1999-09-02 | 2001-03-08 | Leadd B.V. | Apoptin-associating protein |
| EP1081226A1 (de) * | 1999-09-02 | 2001-03-07 | Leadd B.V. | Apoptin-bindendes Protein |
| WO2001042461A2 (en) | 1999-12-10 | 2001-06-14 | Leadd B.V. | Apoptin-associating protein |
| EP1377667B1 (de) * | 2001-03-30 | 2008-11-19 | Leadd B.V. | Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten |
| KR100561985B1 (ko) | 2004-07-03 | 2006-03-22 | 고려대학교 산학협력단 | 종양 특이적 아폽틴 발현 카세트 및 이를 포함하는아데노바이러스 발현 벡터 |
| KR100877824B1 (ko) | 2005-11-11 | 2009-01-12 | 한국생명공학연구원 | Ｅ2ｅｐｆ ｕｃｐ-ｖｈｌ 상호작용 및 그 용도 |
| CN109111527B (zh) * | 2018-08-03 | 2022-03-15 | 沈阳金石生物制药有限公司 | 靶向特异性诱导肿瘤细胞凋亡的gip34-vp3融合蛋白及其制备方法和应用 |
| CN109266714A (zh) * | 2018-10-12 | 2019-01-25 | 广州医科大学 | 一种循环肿瘤细胞的检测方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL9002008A (nl) * | 1990-09-12 | 1992-04-01 | Stichting Centr Diergeneeskund | Recombinant dna en rna en daarvan afgeleide produkten. |
| NL9301272A (nl) * | 1993-07-20 | 1995-02-16 | Aesculaap Bv | Chicken Anemia Virus mutanten en vaccins en toepassingen gebaseerd op de virale eiwitten VP1, VP2 en VP3 of daarvoor coderende sequenties van dat virus. |
| FR2732348B1 (fr) * | 1995-03-31 | 1997-04-30 | Rhone Poulenc Rorer Sa | Systeme d'expression conditionnel |
-
1997
- 1997-11-18 EP EP97203595A patent/EP0878546A1/de not_active Withdrawn
-
1998
- 1998-04-15 CA CA002286165A patent/CA2286165C/en not_active Expired - Fee Related
- 1998-04-15 PL PL336312A patent/PL196607B1/pl unknown
- 1998-04-15 ES ES98914146T patent/ES2227822T3/es not_active Expired - Lifetime
- 1998-04-15 PT PT98914146T patent/PT975764E/pt unknown
- 1998-04-15 BR BR9808542-5A patent/BR9808542A/pt not_active Application Discontinuation
- 1998-04-15 CZ CZ0349399A patent/CZ299963B6/cs not_active IP Right Cessation
- 1998-04-15 AU AU68563/98A patent/AU750162B2/en not_active Ceased
- 1998-04-15 DK DK98914146T patent/DK0975764T3/da active
- 1998-04-15 WO PCT/NL1998/000213 patent/WO1998046760A1/en not_active Ceased
- 1998-04-15 DE DE69825978T patent/DE69825978T2/de not_active Expired - Fee Related
- 1998-04-15 NZ NZ500012A patent/NZ500012A/en unknown
- 1998-04-15 JP JP54377198A patent/JP2001521387A/ja active Pending
- 1998-04-15 AT AT98914146T patent/ATE275200T1/de not_active IP Right Cessation
- 1998-04-15 KR KR10-1999-7009550A patent/KR100528755B1/ko not_active Expired - Fee Related
- 1998-04-15 SK SK1428-99A patent/SK285724B6/sk not_active IP Right Cessation
- 1998-04-15 EP EP98914146A patent/EP0975764B1/de not_active Expired - Lifetime
-
1999
- 1999-10-12 NO NO994967A patent/NO994967L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR100528755B1 (ko) | 2005-11-15 |
| PL336312A1 (en) | 2000-06-19 |
| CZ299963B6 (cs) | 2009-01-07 |
| CZ349399A3 (cs) | 2000-02-16 |
| DE69825978D1 (de) | 2004-10-07 |
| PT975764E (pt) | 2004-11-30 |
| NZ500012A (en) | 2001-04-27 |
| DE69825978T2 (de) | 2005-09-15 |
| SK285724B6 (sk) | 2007-07-06 |
| NO994967D0 (no) | 1999-10-12 |
| PL196607B1 (pl) | 2008-01-31 |
| SK142899A3 (en) | 2000-06-12 |
| WO1998046760A1 (en) | 1998-10-22 |
| CA2286165C (en) | 2009-02-03 |
| KR20010006460A (ko) | 2001-01-26 |
| ATE275200T1 (de) | 2004-09-15 |
| EP0975764B1 (de) | 2004-09-01 |
| CA2286165A1 (en) | 1998-10-22 |
| EP0975764A1 (de) | 2000-02-02 |
| ES2227822T3 (es) | 2005-04-01 |
| JP2001521387A (ja) | 2001-11-06 |
| NO994967L (no) | 1999-12-15 |
| EP0878546A1 (de) | 1998-11-18 |
| BR9808542A (pt) | 2000-05-23 |
| AU750162B2 (en) | 2002-07-11 |
| AU6856398A (en) | 1998-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vile et al. | The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider | |
| NO994967D0 (no) | Gen-avleveringsvehikkel som uttrykker de apoptoseinduserende proteiner VP2 og/eller apoptin | |
| DK0797678T3 (da) | Hybrid adenovirus-AAV-virus og fremgangsmåder til anvendelse af dette | |
| PT797676E (pt) | Vector adenoviral recombinante e metodos de utilizacao | |
| NO20004631L (no) | Forbindelser og fremgangsmÕter for terapi og diagnose av lungekreft | |
| ZA200703294B (en) | Telomelysin-GFPgene-containing recombinant virus | |
| CY1113731T1 (el) | Μεθοδοι για δημιουργια παρασκευασματων κομιστων ανασυνδυασμενου aav υψηλου τιτλου απαλλαγμενων απο βοηθητικο ιο | |
| AU7074698A (en) | Detection and modulation of the iaps and naip for the diagnosis and treatment ofproliferative disease | |
| BR0009505A (pt) | Compostos e processos para terapia e diagnóstico de câncer de pulmão | |
| DE3585790D1 (de) | Varicella-zoster-virus-dns-sequenzen, diese enthaltende vektoren und wirtzellen, uebereinstimmende polypeptide und diese enthaltende verbindungen. | |
| ATE229977T1 (de) | Peptide mit antiproliferativen eigenschaften | |
| CA2167578A1 (en) | Chicken anemia virus mutants and vaccines and uses based on the viral proteins vp1, vp2 and vp3 or sequences of that virus coding therefor | |
| EP1536006A4 (de) | Krebsantigene und deren nutzung | |
| WO1999028461A3 (en) | Methods and means for inducing apoptosis by interfering with bip-like proteins | |
| DE69928395D1 (de) | Cyclin-e2 proteine und dafür kodierende gene | |
| ATE349225T1 (de) | Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv | |
| WO1999028460A3 (en) | Molecules interacting with apoptin | |
| DE69941273D1 (de) | Zusammenstellung und Verfahren zur Diagnose von Tumoren | |
| DK0566571T3 (da) | Diagnose af metastatisk cancer ved hjælp af mts-1-genet | |
| DK498387D0 (da) | Virus-dna-sekvens | |
| NO950420L (no) | Interferon endelse derav | |
| DK0817859T3 (da) | Rekombinante DNA vektorer til Genterapi | |
| NO20005321L (no) | Vertskodet protein uttrykt i Mareks sykdoms (MDV) infiserte celler og antistoffer til dette | |
| CO5050254A1 (es) | Compuestos para el tratamiento y diagnostico del cancer de pulmon |